Here are five things to know:
1. The acquisition closed at $1.045 billion less customary adjustments.
2. The Codman Neurosurgery portfolio includes devices for hydrocephalus, neuro-critical care and operative neurosurgery.
3. The Codman neurosurgery products generated about $370 million in 2016 revenue. This acquisition will situate Integra as a leader in neurosurgical products.
4. Integra possesses a portfolio of tissue ablation, dural repair and cranial stabilization products.
5. Additionally, Integra LifeSciences will soon divest its Camino ICP monitoring product line to Natus for $47.5 million. Natus will also gain U.S. rights associated with Integra’s fixed pressure shunts and Codman’s DURAFORM dural graft implant, standard EVD catheters and CSF collection systems.
More articles on devices:
Finally, a single-use, sterile packed ACDF kit simplified for OR efficiency, introducing the Zavation STERICERV Cervical Instruments Kit
TranS1, CU Innovations partner to bring surgeons’ spine concepts to market: 4 takeaways
Alphatec appoints former NuVasive executive as new executive chairman: 8 notes
